H. Jhoti

发表

High-throughput crystallography to enhance drug discovery.

A. Sharff, H. Jhoti, 2003, Current opinion in chemical biology.

Structure-based Drug Discovery

Andrew R. Leach, A. Leach, H. Jhoti, 2007 .

X-ray crystallographic studies of a series of penicillin-derived asymmetric inhibitors of HIV-1 protease.

P Murray-Rust, R. Cooke, Peter Murray-Rust, 1994, Biochemistry.

A 'rule of three' for fragment-based lead discovery?

M. Congreve, C. Murray, H. Jhoti, 2003, Drug discovery today.

Crystal structure of human cytochrome P450 2C9 with bound warfarin

Jose Cosme, H. Jhoti, Harren Jhoti, 2003, Nature.

Discovery of an allosteric mechanism for the regulation of HCV NS3 protein function

Andrew J. Woodhead, Gianni Chessari, Brent Graham, 2012, Nature chemical biology.

Selecting the Right Targets for Fragment‐Based Drug Discovery

T. G. Davies, Glyn Williams, H. Jhoti, 2016 .

Detection of secondary binding sites in proteins using fragment screening

Marcel L Verdonk, M. Verdonk, H. Jhoti, 2015, Proceedings of the National Academy of Sciences.

Fragment-based screening using X-ray crystallography and NMR spectroscopy.

Glyn Williams, M. Verdonk, H. Jhoti, 2007, Current opinion in chemical biology.

Structure-based screening of low-affinity compounds.

H. Jhoti, R. Carr, Harren Jhoti, 2002, Drug discovery today.

Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.

Christopher W Murray, Alessandro Padova, Jayne Curry, 2005, Journal of medicinal chemistry.

Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors.

Gianni Chessari, Chris Abell, Christopher W Murray, 2006, Journal of medicinal chemistry.

Structural Biology and Anticancer Drug Design

H. Willems, H. Jhoti, D. Tisi, 2014 .

Crystallographic screening using ultra-low-molecular-weight ligands to guide drug design.

Richard J. Hall, C. Murray, H. Jhoti, 2019, Drug discovery today.

Crystallographic screening using ultra-low-molecular-weight ligands to guide drug design.

Richard J. Hall, C. Murray, H. Jhoti, 2019 .

High- Throughput Crystallography for Structural Proteomics

H. Jhoti, J. Yon, M. Vinković, 2005 .

X-ray Crystal Structure of Human Dopamine Sulfotransferase, SULT1A3

A. Hersey, R. Cooke, H. Jhoti, 1999, The Journal of Biological Chemistry.

Thrombin inhibitors based on [5,5] trans-fused indane lactams.

N. Ramsden, H. Jhoti, H. Finch, 1999, Bioorganic & medicinal chemistry letters.

Crystal Structures of Human Cytochrome P450 3A4 Bound to Metyrapone and Progesterone

Jose Cosme, Clemens Vonrhein, C. Vonrhein, 2004, Science.

Fragment-based lead discovery using X-ray crystallography.

Christopher W Murray, Michael J Hartshorn, C. Murray, 2005, Journal of medicinal chemistry.

Novel natural product 5,5-trans-lactone inhibitors of human alpha-thrombin: mechanism of action and structural studies.

C. Wharton, S. Patel, M. Weir, 1998, Biochemistry.

Oxidation state of the active-site cysteine in protein tyrosine phosphatase 1B

Miles Congreve, M. Congreve, H. Jhoti, 2003, Nature.

Molecular structure of serum transferrin at 3. 3-A resolution

H. Jhoti, R. Garratt, R. W. Evans, 1988 .

Twenty years on: the impact of fragments on drug discovery

Harren Jhoti, Wolfgang Jahnke, Daniel A. Erlanson, 2016, Nature Reviews Drug Discovery.

Detection of ligands from a dynamic combinatorial library by X-ray crystallography.

Paul G Wyatt, M. Congreve, H. Jhoti, 2003, Angewandte Chemie.

The epidermolytic toxins are serine proteases

J. Saldanha, H. Jhoti, S. Dancer, 1990, FEBS letters.

Prothoracicotropic hormone has an insulin‐like tertiary structure

T. Blundell, H. Jhoti, H. Nagasawa, 1987, FEBS letters.

A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera.

Ian Collins, Paul Workman, Brent Graham, 2007, Journal of molecular biology.

Crystal structure of human CDK4 in complex with a D-type cyclin

Rajiv Chopra, Jeff Yon, Christoph Lengauer, 2009, Proceedings of the National Academy of Sciences.

CHAPTER 4 – Structural biology and anticancer drug design

Dominic Tisi, Gianni Chessari, Andrew James Woodhead, 2008 .

High‐resolution X‐ray studies on rabbit serum transferrin: preliminary structure analysis of the N‐terminal half‐molecule at 2.3 Å resolution

H. Jhoti, R. Garratt, R. Sarra, 1990 .

High-throughput protein crystallography and drug discovery.

Ian Tickle, Jeff Yon, Andrew Sharff, 2004, Chemical Society reviews.

High-throughput structural genomics and proteomics: where are we now?

H. Jhoti, J. Yon, 2003 .

The Discovery of Novel Protein Kinase Inhibitors by Using Fragment‐Based High‐Throughput X‐ray Crystallography

H. Jhoti, A. Gill, Harren Jhoti, 2005, Chembiochem : a European journal of chemical biology.

Fragment-based drug discovery using rational design.

H. Jhoti, H Jhoti, 2007, Ernst Schering Foundation symposium proceedings.

Pyramid: An Integrated Platform for Fragment‐based Drug Discovery

Harren Jhoti, Rob L. M. van Montfort, T. G. Davies, 2006 .

High-throughput crystallography for lead discovery in drug design

Harren Jhoti, Tom L. Blundell, Chris Abell, 2002, Nature Reviews Drug Discovery.

Crystallization and preliminary analysis of an 18,000 Mr fragment of duck ovotransferrin.

H. Jhoti, R. Garratt, R. W. Evans, 1988, Journal of molecular biology.

Protein–Protein Interactions: Putting the pieces together

H. Jhoti, B. Bax, 1995, Current Biology.

The 'rule of three' for fragment-based drug discovery: where are we now?

Harren Jhoti, Glyn Williams, Christopher W. Murray, 2013, Nature Reviews Drug Discovery.

The structure of rat ADP-ribosylation factor-1 (ARF-1) complexed to GDP determined from two different crystal forms

H. Jhoti, R. Solari, S. Cockcroft, 1995, Nature Structural Biology.

High-throughput screening and structure-based approaches to hit discovery: is there a clear winner?

Harren Jhoti, Stephen Rees, Roberto Solari, 2013, Expert opinion on drug discovery.

High-throughput X-ray techniques and drug discovery.

H Jhoti, H. Jhoti, 2003, Ernst Schering Research Foundation workshop.

A new school for screening

H. Jhoti, Harren Jhoti, 2005, Nature Biotechnology.

Fragment-based drug discovery using cryo-EM.

M. Hartshorn, H. Jhoti, M. Saur, 2019, Drug discovery today.

Fragments: where are we now?

Harren Jhoti, James Osborne, Stanislava Panova, 2020, Biochemical Society transactions.

A molecular model for the tumour‐associated antigen, p97, suggests a Zn‐binding function

H. Jhoti, R. Garratt, 1992, FEBS letters.

The mechanism of iron uptake by transferrins: the structure of an 18 kDa NII-domain fragment from duck ovotransferrin at 2.3 A resolution.

R. Strange, H. Jhoti, R. Garratt, 1993, Acta crystallographica. Section D, Biological crystallography.

Crystal Structure of Human Soluble Adenylate Cyclase Reveals a Distinct, Highly Flexible Allosteric Bicarbonate Binding Pocket

M. Congreve, C. Murray, V. Berdini, 2014, ChemMedChem.

Automated Protein–Ligand Crystallography for Structure‐Based Drug Design

Marcel L Verdonk, Michael J Hartshorn, Wijnand T M Mooij, 2006, ChemMedChem.